The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is entering a period of robust expansion, with its global valuation estimated at $2.14$ billion in 2025 and projected to reach $4.33$ billion by 2035. This growth, representing a compound annual growth rate (CAGR) of approximately $7.3\%$, is driven by the rising prevalence of autoimmune neurological disorders and an aging global population. For a comprehensive breakdown of market size and long-term forecasts, you can explore the CIDP Market report.

People also ask: What is the market size of CIDP? Why is the CIDP market growing? The increase in healthcare expenditure and the development of specialized neurological clinics are major contributors to this upward trend. As clinical research clarifies the underlying mechanisms of demyelination, the market is seeing a surge in investment for targeted biological therapies.

Furthermore, the expansion of healthcare insurance coverage in emerging economies is making high-cost treatments more accessible. This democratization of care ensures that a larger portion of the global patient pool can receive long-term maintenance therapy, stabilizing market revenue through recurring treatment cycles.